皮肤鳞状细胞癌生物治疗的研究进展OA

Cutaneous squamous cell carcinoma(cSCC)is a common malignant tumor of the skin.Early-stage patients can achieve good prognosis through treatment methods such as surgery and radiation therapy,but there are still some who pro-gress to the advanced stage with poor prognosis.In recent years,with a deeper understanding of the molecular mechanisms of cSCC—including gene mutations(e.g.,TP53 and Notch),pathway aberrations(e.g.,EGFR signaling),high tumor mu-tational burden,and an immunosuppressive microenvironment—the treatment of cSCC has entered the era of biologic thera-py.Targeted therapy represented by EGFR inhibitors(such as cetuximab)and immunotherapy centered around programmed death-1 inhibitors(such as cemiplimab)have become important choices for advanced patients,with immunotherapy becom-ing a first-line option.Combination therapy strategies,such as targeted therapy plus immunotherapy,have also shown the po-tential to enhance efficacy and overcome drug resistance.This article will systematically review the clinical application pro-gress of drugs related to targeted therapy,immunotherapy,and their combination in cSCC.